Ballew Advisors’s GSK GSK Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2025
Q2 | $373K | Buy |
9,759
+1
| +0% | +$38 | 0.22% | 78 |
|
2025
Q1 | $338K | Hold |
9,758
| – | – | 0.23% | 80 |
|
2024
Q4 | $319K | Sell |
9,758
-372
| -4% | -$12.2K | 0.2% | 83 |
|
2024
Q3 | $408K | Hold |
10,130
| – | – | 0.27% | 71 |
|
2024
Q2 | $392K | Buy |
10,130
+29
| +0.3% | +$1.12K | 0.26% | 75 |
|
2024
Q1 | $411K | Hold |
10,101
| – | – | 0.28% | 75 |
|
2023
Q4 | $403K | Buy |
10,101
+9
| +0.1% | +$359 | 0.3% | 73 |
|
2023
Q3 | $364K | Buy |
10,092
+5
| +0% | +$180 | 0.3% | 73 |
|
2023
Q2 | $344K | Hold |
10,087
| – | – | 0.25% | 78 |
|
2023
Q1 | $358K | Buy |
10,087
+8
| +0.1% | +$284 | 0.26% | 77 |
|
2022
Q4 | $354K | Hold |
10,079
| – | – | 0.27% | 71 |
|
2022
Q3 | $304K | Buy |
10,079
+5
| +0% | +$151 | 0.27% | 73 |
|
2022
Q2 | $506K | Buy |
10,074
+4
| +0% | +$201 | 0.46% | 52 |
|
2022
Q1 | $590K | Buy |
10,070
+352
| +4% | +$20.6K | 0.45% | 52 |
|
2021
Q4 | $552K | Buy |
9,718
+1
| +0% | +$57 | 0.38% | 65 |
|
2021
Q3 | $470K | Hold |
9,717
| – | – | 0.35% | 66 |
|
2021
Q2 | $492K | Sell |
9,717
-9,710
| -50% | -$492K | 0.34% | 68 |
|
2021
Q1 | $870K | Buy |
19,427
+9,715
| +100% | +$435K | 0.32% | 69 |
|
2020
Q4 | $460K | Buy |
9,712
+112
| +1% | +$5.31K | 0.35% | 62 |
|
2020
Q3 | $452K | Hold |
9,600
| – | – | 0.38% | 53 |
|
2020
Q2 | $485K | Hold |
9,600
| – | – | 0.48% | 43 |
|
2020
Q1 | $455K | Hold |
9,600
| – | – | 0.51% | 35 |
|
2019
Q4 | $560K | Hold |
9,600
| – | – | 0.48% | 44 |
|
2019
Q3 | $503K | Hold |
9,600
| – | – | 0.46% | 49 |
|
2019
Q2 | $491K | Hold |
9,600
| – | – | 0.45% | 51 |
|
2019
Q1 | $486K | Hold |
9,600
| – | – | 0.45% | 49 |
|
2018
Q4 | $493K | Hold |
9,600
| – | – | 0.46% | 47 |
|
2018
Q3 | $472K | Hold |
9,600
| – | – | 0.43% | 50 |
|
2018
Q2 | $484K | Hold |
9,600
| – | – | 0.55% | 43 |
|
2018
Q1 | $469K | Hold |
9,600
| – | – | 0.41% | 53 |
|
2017
Q4 | $426K | Buy |
+9,600
| New | +$426K | 0.42% | 52 |
|